UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nitric oxide and cancer: the emerging role of S-nitrosylation

Current molecular medicine, 2012-01, Vol.12 (1), p.50-67

2012

Volltextzugriff (PDF)

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of oncology, 2012-12, Vol.23 (12), p.3069-3074

2012

Volltextzugriff (PDF)

Fulvestrant in advanced male breast cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1896-1897

2009

Volltextzugriff (PDF)

Abstract P1-13-09: Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-13-09

2016

Volltextzugriff (PDF)

First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1112-1112

2011

Volltextzugriff (PDF)

Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e21105-e21105

2011

Volltextzugriff (PDF)

Breast cancer screening: another point of view

European journal of cancer prevention, 2005-02, Vol.14 (1), p.1-5

2005

Volltextzugriff (PDF)

Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.S1-S1-7

2012

Volltextzugriff (PDF)

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of oncology, 2012-12, Vol.23 (12), p.3069

2012

Volltextzugriff (PDF)

OT3-01-15: Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The LEA Study

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT3-01-15-OT3-01-15

2011

Volltextzugriff (PDF)

Fulvestrant in advanced male breast cancer

Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Vol.20 (11), p.1896-1897

2009

Volltextzugriff (PDF)

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Clinical & translational oncology, 2017-12, Vol.19 (12), p.1454-1461

2017

Volltextzugriff (PDF)

Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index

British journal of cancer, 2017-04, Vol.116 (8), p.994-1001

2017

Volltextzugriff (PDF)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

British journal of cancer, 2014-03, Vol.110 (5), p.1139-1147

2014

Volltextzugriff (PDF)

Metagenomes of a Crystallizer Pond from Isla Cristina Saltern in Spain

Microbiology resource announcements, 2023-05, Vol.12 (5), p.e0003923-e0003923

2023

Volltextzugriff (PDF)

On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism

Thrombosis research, 2016-07, Vol.143, p.76-85

2016

Volltextzugriff (PDF)

281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays

Annals of oncology, 2024-09, Vol.35, p.S332-S333

2024

Volltextzugriff (PDF)

Endothelial nitric oxide synthase in colorectal cancer: A potential new therapeutic target in stem cell-like poor-prognosis subtype

European journal of cancer (1990), 2016-12, Vol.69, p.S46-S46

2016

Volltextzugriff (PDF)

Draft Genome Sequence of Saccharomonospora piscinae KCTC 19743 T , an Actinobacterium Containing Secondary Metabolite Biosynthetic Gene Clusters

Microbiology resource announcements, 2020-04, Vol.9 (15)

2020

Volltextzugriff (PDF)

Long-term echocardiographic assessment of descendants of gestational breast cancer patients exposed to anthracycline-based chemotherapy

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-17

2019

Volltextzugriff (PDF)

Draft Genome Sequences of Salinivibrio proteolyticus, Salinivibrio sharmensis, Salinivibrio siamensis, Salinivibrio costicola subsp. alcaliphilus , Salinivibrio costicola subsp. vallismortis , and 29 New Isolates Belonging to the Genus Salinivibrio

Genome announcements (Washington, DC), 2017-07, Vol.5 (27)

2017

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Humans
(17)
Middle Aged
(14)
Oncology
(14)
Aged
(13)
Female
(13)
Adult
(11)
Breast Neoplasms - Drug Therapy
(9)
Biological And Medical Sciences
(8)
Prognosis
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Breast Cancer
(6)
Neoplasm Staging
(6)
Tumors
(6)
Animals
(5)
Breast Neoplasms - Pathology
(5)
Cancer
(5)
Male
(5)
Medical Sciences
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Nitric oxide and cancer: the emerging role of S-nitrosylation

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Fulvestrant in advanced male breast cancer

Abstract P1-13-09: Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients

First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis

Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy

Breast cancer screening: another point of view

Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

OT3-01-15: Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The LEA Study

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Fulvestrant in advanced male breast cancer

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Metagenomes of a Crystallizer Pond from Isla Cristina Saltern in Spain

On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism

281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays

Endothelial nitric oxide synthase in colorectal cancer: A potential new therapeutic target in stem cell-like poor-prognosis subtype

Draft Genome Sequence of Saccharomonospora piscinae KCTC 19743 T , an Actinobacterium Containing Secondary Metabolite Biosynthetic Gene Clusters

EP08.01-048 Spanish Immunotherapy Registry of Cardiovascular Toxicity (SIR-CVT): Preliminary Analysis of the Lung Cancer Cohort

Long-term echocardiographic assessment of descendants of gestational breast cancer patients exposed to anthracycline-based chemotherapy

Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population

Draft Genome Sequences of Salinivibrio proteolyticus, Salinivibrio sharmensis, Salinivibrio siamensis, Salinivibrio costicola subsp. alcaliphilus , Salinivibrio costicola subsp. vallismortis , and 29 New Isolates Belonging to the Genus Salinivibrio

Suchergebnisse filtern